Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovateltide in mild to moderate Alzheimer's disease
NCT04052737Phase 2Completed
- Sponsor
- Pharmazz, Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Sovateltide + SOC with Placebo + SOC (2 arms). Primary endpoints: Incidence of PMZ-1620 related adverse events at 160 days and Number of patients not receiving full treatment due to intolerance to PMZ-1620 at 160 days. Started Mar 2018; status: completed.
02
Drugs
sovateltide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04052737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052737.